ADX-001, A Novel Hypoimmunogenic, Half-life Extended Anti-TNFα/IL-23p19 Bispecific Antibody for Inflammatory Disease (ACR Convergence 2026) - Sep 8, 2026 - Abstract #2079; Pres time: Nov 10, 2026; 10:30 AM - 12:30 PM; Location: WB1&2; In Person; "ADX-001 is a novel hypoimmunogenic anti-TNFα/IL-23p19 bispecific antibody offering a promising therapeutic advancement for inflammatory indications by improving efficacy over monotherapies, minimizing immunogenicity risks, and providing a more streamlined and patient-friendly dosing regimen. ADX-001 is currently in IND-enabling studies with a projected Phase 1 initiation in Q4 2026. ADX-001, containing conjugated CD22Ls, suppresses ADA titers (A), and rescues the pharmacokinetics (PK) in (B) in B6-hFcRn knock-in mice following 4 weekly subcutaneous injections at 4mg/kg"
Bispecific • Gastroenterology • Gastrointestinal Disorder • Inflammation • Inflammatory Arthritis • Inflammatory Bowel Disease • Psoriatic Arthritis • Seronegative Spondyloarthropathies • CD22
|
|
Kwok-ho Lam, Robert Morse, Sandra DePorter, Angeline Ta, Jiawei Wang, Chi Tran, Scott Lashbrook, Prathna Srinivas, Madison Tomison, David Plouffe, Manny Corpuz, Richard Orcutt, Holly Pugh, François Vermersch, Grant Gabrelow, Joshua Knauer, Vincent Lieuw, Maribelle Amour, Juliae Shoda, Jessica Field, Dikran Aivazian; Andrew Miller
|